Tamar BenYedidia - BiondVax Pharmaceuticals Chief Scientific Officer
| BVXVDelisted Stock | USD 1.35 0.03 2.17% |
Executive
Dr. Tamar BenYididia serves as Chief Scientific Officer at Biondvax Pharmaceuticals Ltd since 2004. Her work experience includes the following roles Lab Manager at Biotechnology General Ltd and Research Associate at Weizmann Institute of ScienceDepartment of Immunology . Dr. BenYedidia was involved in two European Consortium projects related to the evaluation of different approaches for vaccination, was invited to address conferences worldwide since 2004.
| Age | 59 |
| Tenure | 20 years |
| Phone | 972 8 930 2529 |
| Web | https://www.biondvax.com |
BiondVax Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.3089) % which means that it has lost $0.3089 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (56.0153) %, meaning that it created substantial loss on money invested by shareholders. BiondVax Pharmaceuticals' management efficiency ratios could be used to measure how well BiondVax Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.BiondVax Pharmaceuticals currently holds 21.54 M in liabilities. BiondVax Pharmaceuticals has a current ratio of 1.68, which is within standard range for the sector. Note, when we think about BiondVax Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Sari Fishman | Can Fite Biopharma | 52 | |
| Pamela Trail | Molecular Partners AG | 68 | |
| Mark Conley | SAB Biotherapeutics | N/A | |
| Renate Gloggner | Molecular Partners AG | 54 | |
| Jaya Goyal | PepGen | 56 | |
| Hayley Parker | PepGen | N/A | |
| Robert Hendriks | Molecular Partners AG | N/A | |
| Netanel Derovan | Oramed Pharmaceuticals | 48 | |
| Andrew Taubman | Adial Pharmaceuticals | N/A | |
| Calais Pharm | Transcode Therapeutics | 65 | |
| Sarah Foster | Mineralys Therapeutics, Common | N/A | |
| MPH MD | Salarius Pharmaceuticals | N/A | |
| Cindy Berejikian | Mineralys Therapeutics, Common | N/A | |
| MBA CFA | PepGen | N/A | |
| Mary JD | PepGen | 56 | |
| Emiko Bryant | PepGen | N/A | |
| Stefan Abele | Pharvaris BV | 54 | |
| David MD | Mineralys Therapeutics, Common | 69 | |
| Ety MBA | Mediwound | 62 | |
| MD FACP | Can Fite Biopharma | N/A | |
| Afsaneh Mohebbi | PepGen | N/A | |
Management Performance
| Return On Equity | -56.02 | |||
| Return On Asset | -0.31 |
BiondVax Pharmaceuticals Leadership Team
Elected by the shareholders, the BiondVax Pharmaceuticals' board of directors comprises two types of representatives: BiondVax Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BiondVax. The board's role is to monitor BiondVax Pharmaceuticals' management team and ensure that shareholders' interests are well served. BiondVax Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BiondVax Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Chief Officer | ||
| BSc Eng, Chief Officer | ||
| Tamar BenYedidia, Chief Scientific Officer | ||
| Dalit Fischer, Head RD | ||
| MSc MBA, CEO Director | ||
| Moran LLB, Chief Staff |
BiondVax Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BiondVax Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -56.02 | |||
| Return On Asset | -0.31 | |||
| Current Valuation | 21.94 M | |||
| Shares Outstanding | 3.65 M | |||
| Shares Owned By Insiders | 20.01 % | |||
| Shares Owned By Institutions | 10.69 % | |||
| Number Of Shares Shorted | 4.88 K | |||
| Price To Earning | (4.91) X | |||
| Price To Book | 7.48 X | |||
| EBITDA | (10.5 M) |
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Other Consideration for investing in BiondVax Stock
If you are still planning to invest in BiondVax Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BiondVax Pharmaceuticals' history and understand the potential risks before investing.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Stocks Directory Find actively traded stocks across global markets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |